Allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses SARASOTA, FLA., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent platform, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent applicati

HitGen Inc. (“HitGen”, SSE: 688222.SH) announced on September 17, 2026, that its wholly owned Hong Kong subsidiary, HitGen (HK) Ltd., has jointly invested in Connexus Therapeutics (“Connexus”) alongside OrbiMed Asia Partners, LAV, and Panku Capital Limited (a wholly owned subsidiary of Biokin Pharmaceutical). Connexus is a preclinical-stage biotechnology company focused on developing novel small molecule oncology therapeutics. HitGen (HK) Ltd. is the founding shareholder of Connexus. Under the a

Distribution of Nitronox Plus expands patient comfort options for office-based gynecology procedures, while the recent launch of HERizon Vista supports in-office hysteroscopic visualization and diagnosis-driven AUB care. SUNNYVALE, CA / ACCESS Newswire / September 18, 2026 / Axora Medical announced a partnership with Porter Instrument, a division of Parker Hannifin Corporation, to distribute the Nitronox Plus nitrous oxide and oxygen delivery system to gynecology practices throughout the Un

If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹ Recommendation based on data showing Cos entyx doubled sus tained remission rates and delivered steroid sparing effects vs placebo ; safety was consistent with established Cosentyx profile² Despite being a common inflammatory rheumatic disease in people over 50, there are limited advanced treatments for PMR; extended u

COLUMBUS, Ohio , Sept. 18, 2026 /PRNewswire/ -- Andelyn Biosciences ("Andelyn"), a leading, patient-focused cell and gene therapy Contract Development and Manufacturing Organization ("CDMO"), today announced it is now manufacturing FAYUVI™ (rebisufligene etisparvovec-hopf), an FDA-approved gene therapy, for commercial supply at its Columbus, Ohio facility. The announcement follows the U.S. Food and Drug Administration's approval of Ultragenyx Pharmaceutical Inc.'s FAYUVI™ for treating Sanfilip

SAN DIEGO--(BUSINESS WIRE)-- $ARCT #65Roses --Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will host a virtual presentation on Wednesday, September 23, 2026, at 4:30 p.m. ET. The presentation will provide an overview of the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) deficiency and Arcturus’ mRNA live

October 9-12, 2026 | Phoenix, Arizona -- New data spans pharmacotherapy, imaging and diagnostics, and device therapy for patients with cardiomyopathy WASHINGTON , Sept. 18, 2026 / PRNewswire / -- The Heart Failure Society of America ( HFSA ) today announced the Late-Breaking Clinical Research slate for its Annual Scientific Meeting ( ASM ), October 9-12, 2026, at the Phoenix Convention Center in Phoenix, Arizona. This year's late-breaking program spans pharmacotherapy, imaging and diagnostic

RUTHERFORD, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), today announced that The University of Alabama’s Culverhouse College of Business will continue its participation in the ai² Pipeline division for the upcoming academic year. The renewed collaboration extends a hands-on program in which students evaluate real-world biopharmaceutical business development and asset assessment opportunities. The program also supports Lōkahi’s

- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production BRIDGEWATER, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product references SOMATULINE ® Depot and will launch

WALTHAM, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on September 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchas